Table 1.
Clinical evidence on impact of quinazoline α1-antagonists on prostate cancer
| Study | Risk Ratio | Odds Ratio | Drug (s) | Drug Class | Source |
|---|---|---|---|---|---|
| Harris et al. | 0.683 (95% CI 0.532-0.8776) | N/A | Doxazosin, prazosin, terazosin | Quinazolines | [102] |
| Van Rompay et al. | 0.89 (95% CI 0.81-0.97) | N/A | Alfuzosin, doxazosin, prazosin, terazosin, or tamsulosin | Quinazolines (4), Sulfonamide (1) | [103] |
| Friedman et al. | N/A | 1.17, 1.22 (95% CI 1.11-1.24, 1.16-1.29) | Prazosin, terazosin | Quinazolines | [104] |
Epidemiological studies observing the relative odds or risk of developing prostate cancer amongst individuals treated with different α1-adrenoceptor antagonists.